Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

53.70 -0.34 (-0.63%)
Streaming Delayed Price Updated: 3:09 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
NYSE:GMED qualifies as a high growth stock and is consolidating.
GLOBUS MEDICAL INC - A (NYSE:GMED)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Investors seeking growth at a reasonable cost should explore NYSE:GMED.
In the world of growth stocks, NYSE:GMED shines as a value proposition. 
Via Chartmill
Assessing Globus Medical: Insights From 5 Financial Analysts
 
Via Benzinga
3 Stocks at the Forefront of Medical Robotics
Although the concept of medical robotics stocks is incredibly risky, the sector also offers tremendous upside for the intrepid. 
Via InvestorPlace
For those who appreciate growth without the sticker shock, NYSE:GMED is worth considering.
GLOBUS MEDICAL INC - A (NYSE:GMED) is not too expensive for the growth it is showing. 
Via Chartmill
NYSE:GMED: a strong growth stock preparing for the next leg up?.
GLOBUS MEDICAL INC - A (NYSE:GMED) qualifies as a high growth stock and is consolidating. 
Via Chartmill
Investors should take note of NYSE:GMED, a growth stock that remains attractively priced.
Despite its growth, NYSE:GMED remains within the realm of affordability. 
Via Chartmill
Expert Ratings for Globus Medical
 
Via Benzinga
Globus Medical: Q3 Earnings Insights
 
Via Benzinga
NYSE:GMED is showing good growth, while it is not too expensive.
NYSE:GMED, a growth stock which is not overvalued. 
Via Chartmill
Globus Medical (GMED) Q3 2023 Earnings Call Transcript
GMED earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Globus Medical Reports Third Quarter 2023 Results
From Globus Medical
Via GlobeNewswire
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting
From Globus Medical
Via GlobeNewswire
What 8 Analyst Ratings Have To Say About Globus Medical
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
 
Via Benzinga
Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum
From Globus Medical
Via GlobeNewswire
Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023
From Globus Medical
Via GlobeNewswire
The Latest Analyst Ratings for Globus Medical
 
Via Benzinga
Where Globus Medical Stands With Analysts
 
Via Benzinga
Globus Medical's Untapped Potential Beyond The NUVA Transaction; Analyst Turns Bullish
Stifel analyst Mathew Blackman upgraded Globus Medical, Inc. (NYSE: GMED) to Buy from Hold, 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
 
Via Benzinga
NuVasive Specialized Orthopedics Launches Precice Bone Transport in International Markets
From Globus Medical
Via GlobeNewswire
Globus Medical (GMED) Q2 2023 Earnings Call Transcript
GMED earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Expert Ratings for Globus Medical
 
Via Benzinga
Globus Medical Completes Merger with NuVasive
From Globus Medical
Via GlobeNewswire
Globus Medical Reports Second Quarter 2023 Results
From Globus Medical
Via GlobeNewswire
Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the company’s first product designed specifically for early onset scoliosis
MARVEL™ is Globus Medical’s second major release this year in the pediatric scoliosis space 
From Globus Medical
Via GlobeNewswire
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
From Globus Medical
Via GlobeNewswire
Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis
REFLECT™ is approved through the FDA’s Humanitarian Device Exemption pathway 
From Globus Medical
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.